AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Helmerich & Payne, Inc. (H&P) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 8 December 2025 in which we reassessed the appropriateness of the ratings in ...
A director at Helmerich & Payne Inc sold 6,681 shares at 30.230USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. De...
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Repo...
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg ...
atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the votes cast at the Extraordinary General Meeting in favor of the transactionsAtaiBeckley has an industry-leading pipeline of investigational treatments, led by BPL-003 (...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.